Most notably, with corroborating data analysis and in vitro validation, PAFAH1B3 is identified as not merely overexpressed but also stands as a promising candidate for a potent prognostic biomarker and therapeutic target in lung cancer. Here, PAFAH1B3 is linked to lung carcinoma.